Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Scottsdale, Arizona 85259


The purpose of this study is to determine the safety and tolerability of dasatinib when given in combination with lenalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma.


Inclusion Criteria: - Able to provide written informed consent - Men and women age ≥ 18 years - Confirmed diagnosis of MM with measurable disease - Evidence of relapsed or refractory disease and at least one prior therapy for MM - ECOG Performance Status 0 - 2 - Last MM treatment not within 21 days prior to study treatment initiation - BMT not within 3 months prior to study treatment initiation - Required baseline hematology and chemistry parameters Exclusion Criteria: - Clinically significant cardiac disease (NYHA Class III or IV) - Abnormal QTcF interval prolonged (> 450 msec) - Malabsorption syndrome or uncontrolled gastrointestinal toxicities - Clinically significant pleural effusion in the previous 12 months or current ascitis - Clinically-significant coagulation or platelet function disorder - Intolerance to dasatinib and/or lenalidomide - Subjects with a history of severe rash, hypersensitivity reaction or anaphylaxis related to prior thalidomide treatment



Primary Contact:

Study Director
Bristol-Myers Squibb
Bristol-Myers Squibb

Backup Contact:


Location Contact:

Scottsdale, Arizona 85259
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.